Abstract | INTRODUCTION: OBJECTIVES: METHODS: The following electronic databases were searched up to November 2010: MEDLINE, EMBASE, and the Cochrane Library. Additional references were obtained from the reviewed articles. Only randomized controlled trials of at least 12-week duration with basal-bolus regimen therapies using detemir insulin vs. NPH insulin were included. RESULTS: The analysis included 10 studies involving 3825 patients with type 1 diabetes. Combined data from all trials showed a statistically significant reduction in hemoglobin A1c (HbA1c) (weighted mean difference: [WMD] -0.073, 95% CI -0.135 to -0.011, P = 0.021) in the detemir group compared with the NPH group. There was also a significant reduction of fasting plasma glucose (FPG) (WMD - 0.977 mmol/l, 95% CI -1.395 to -0.558, P <0.001), all-day hypoglycemic episodes (relative risk [RR] 0.978, 95% CI 0.961-0.996), severe hypoglycemic episodes (RR 0.665, 95% CI 0.547-0.810), nocturnal hypoglycemic episodes (RR 0.877, 95% CI 0.816-0.942), as well as smaller body weight gain (WMD -0.779 kg, 95% CI -0.992 to -0.567) in patients using detemir insulin compared with those using NPH insulin. CONCLUSIONS:
|
Authors | Agnieszka Szypowska, Dominik Golicki, Lidia Groele, Ewa Pańkowska |
Journal | Polskie Archiwum Medycyny Wewnetrznej
(Pol Arch Med Wewn)
2011 Jul-Aug
Vol. 121
Issue 7-8
Pg. 237-46 Poland |
PMID | 21878861
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Blood Glucose
- Delayed-Action Preparations
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin, Long-Acting
- Insulin Detemir
|
Topics |
- Blood Glucose
(drug effects)
- Body Weight
(drug effects)
- Delayed-Action Preparations
- Diabetes Mellitus, Type 1
(drug therapy, prevention & control)
- Drug Administration Schedule
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin Detemir
- Insulin, Long-Acting
(therapeutic use)
- Randomized Controlled Trials as Topic
|